Karo divests portfolio of brands to Evolan

2 July 2021 - Deborah Wilkes

Premium

Sweden’s Karo Pharma has divested a portfolio of consumer healthcare and prescription brands – which are “not in line with its growth strategy” – to Evolan Pharma for an undisclosed sum.

Click tags below for more information on topics:

Karo Pharma

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: